Interesting design aspect of IONIC trial: Group 1: Patients who...

Interesting design aspect of IONIC trial:

Group 1: Patients who are already receiving a checkpoint inhibitor and have minor disease progression. The current checkpoint inhibitor will be switched to nivolumab and NOX66 will be added. The study aim in the first group is to determine whether the addition of NOX66 to nivolumab specifically can convert a non-response to checkpoint inhibitors into a response.

This means that IONIC will accept a patient who has just failed Keytruda - just imagine how BMS will feel if that patient then responds to Opdivo plus NOX66!